Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) reached a new 52-week high on Thursday . The stock traded as high as $5.40 and last traded at $5.14, with a volume of 20745 shares. The stock had previously closed at $4.79.
Analyst Ratings Changes
Several equities research analysts have weighed in on CMPX shares. Raymond James upped their target price on Compass Therapeutics from $5.00 to $8.00 and gave the stock an "outperform" rating in a research note on Thursday, November 10th. EF Hutton Acquisition Co. I started coverage on Compass Therapeutics in a research note on Friday, December 16th. They set a "buy" rating and a $10.30 target price for the company. HC Wainwright cut their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, November 3rd. Finally, LADENBURG THALM/SH SH upped their target price on Compass Therapeutics to $9.00 in a research note on Wednesday, November 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $9.46.
Get Compass Therapeutics alerts:Compass Therapeutics Stock Performance
The firm's fifty day moving average price is $4.00 and its 200-day moving average price is $3.18.
Compass Therapeutics (NASDAQ:CMPX – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Research analysts predict that Compass Therapeutics, Inc. will post -0.39 EPS for the current fiscal year.Insider Transactions at Compass Therapeutics
In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $34,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,421,873 shares of the company's stock, valued at approximately $12,307,651.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $34,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,421,873 shares of the company's stock, valued at approximately $12,307,651.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc acquired 402,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 8th. The stock was bought at an average price of $3.21 per share, with a total value of $1,290,420.00. Following the completion of the acquisition, the director now directly owns 15,219,994 shares of the company's stock, valued at $48,856,180.74. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 427,000 shares of company stock worth $1,347,670. Corporate insiders own 29.80% of the company's stock.
Institutional Trading of Compass Therapeutics
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Compass Therapeutics by 58.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company's stock worth $5,428,000 after acquiring an additional 878,650 shares during the period. Eventide Asset Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter worth about $2,509,000. BlackRock Inc. boosted its position in shares of Compass Therapeutics by 433.9% during the 3rd quarter. BlackRock Inc. now owns 872,497 shares of the company's stock worth $1,989,000 after purchasing an additional 709,071 shares in the last quarter. Silverarc Capital Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter worth about $598,000. Finally, Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 397.5% during the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company's stock worth $175,000 after purchasing an additional 52,865 shares in the last quarter. 54.27% of the stock is currently owned by institutional investors and hedge funds.
About Compass Therapeutics
(Get Rating)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
Featured Articles
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.